Abstract: A novel process has been developed for the treatment of crosslinked ethylene-propylene diene monomer (EPDM) elastomer material to decrease its residual peroxide levels. EPDM is used to form the seats and neck gaskets of metering valves used in metered-dose inhalers (MDI). For filled and inverted MDI units these EPDM components are in direct contact with the pharmaceutical formulation media. The process involves exposing the EPDM valve components to a solution of 2-mercaptoethanol, a chemical reducing agent. The 2-mercaptoethanol greatly diminishes the residual peroxide levels in EPDM by reducing the peroxide functional groups to the corresponding hydroxyl groups. EPDM components treated in this manner have demonstrated very low peroxide levels and, consequently, greatly improved compatibility with the pharmaceutical formulation in the inhaler. An advantage of this approach is that the treated EPDM would likely retain its favorable physical properties and its good performance in metering valves.

Abstract: The invention is a pharmaceutical composition for intravenous administration to a patient comprisinga) a pharmaceutically effective amount of 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid;b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; andc) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient.

Abstract: A composition is disclosed comprising about 0.25 mg/ml 2-S-(n-Butylsulfonylamino)-3 -[4-(4-(piperdin-4-yl)butyloxylphenyl]propionic acid, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, about 0.16 mg/ml citric acid anhydrous, wherein the composition osmolality concentration is between about 250-310 mOsmol/kg and the pH is in the range of between 5.5-6.5.

Abstract: The invention is a pharmaceutical composition for intravenous administration to a patient comprisinga) a pharmaceutically effective amount of a compound having the formula ##STR1## as 2-S-(n-Butylsulfonylamino)-3-?4-(4-(piperidin-4-yl)butyloxy)phenyl!propion ic acid;b) a pharmaceutically acceptable amount of a citrate buffer effective to provide a pH of between about 5 and 7; andc) a pharmaceutically acceptable amount of a tonicity adjusting agent effective to make the formulation substantially isotonic with the osmotic pressure of the biological system of the patient.